In May 2000, Morphotek is founded by Drs. Luigi Grasso, Nicholas Nicolaides and Phillip Sass. Morphotek is an emerging biopharmaceutical company committed to developing novel classes of biological-based products to treat cancer, inflammation, neovascular and infectious diseases. It is the company's belief that monoclonal antibodies (MAbs), which represent the fastest growing segment of the biopharmaceutical market, hold the greatest promise to treat and eradicate human disease.